GleamWall
中文EN

AMLX Amylyx Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1658551 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-100.3%
TTM net income YoY42.5%
TTM EPS YoY53.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin100.0%
Operating margin23,660.3%
Net margin22,448.4%
FCF margin23,236.1%
EBITDA margin23,573.5%

Returns

ROE-56.5%
ROA-48.7%
ROIC (approx.)-107.5%
Asset turnover-0.00x

Leverage & solvency

Liabilities / assets8.5%
Debt / equity0.00x
Current ratio13.70x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.03x
Accruals ratio1.7%
Payout ratio—
Capex / revenue-10.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———$0$0$0$0-$665,000
Cost of revenue———$0$0$0$0$0
Gross profit———$0$0$0$0-$665,000
R&D expense$28.35M$23.77M$27.61M$21.21M$19.86M$27.22M$22.12M$22.89M
SG&A expense$21.31M$21.93M$16.17M$15.39M$16.17M$15.64M$15.68M$17.10M
Operating income-$49.66M-$45.69M-$43.78M-$36.60M-$36.03M-$42.86M-$37.80M-$40.65M
Pretax income———-$32.95M-$34.39M-$41.44M-$35.91M-$38.18M
Income tax———$46,000$0$0$0-$635,000
Net income-$45.49M-$43.42M-$41.28M-$33.00M-$34.39M-$41.44M-$35.91M-$37.55M
EBITDA-$49.62M-$45.65M-$43.68M-$36.50M-$35.91M-$42.72M-$37.65M-$40.49M
EPS (basic)-0.38-0.39-0.37—-0.37-0.46-0.42—
EPS (diluted)-0.38-0.39-0.37—-0.37-0.46-0.42—
Weighted avg. shares (diluted)118.94M111.20M110.56M—93.33M89.14M85.70M—
Balance sheet
Cash & equivalents$240.09M$49.33M$229.14M$226.65M$225.18M$58.09M$59.76M$77.39M
Short-term investments$528.04M$201.43M$50.63M$90.33M$118.81M$122.74M$144.30M$99.11M
Receivables———$88,000$132,000$103,000$300,000$447,000
Current assets$778.86M$256.34M$285.02M$323.67M$353.38M$186.89M$216.14M$189.43M
PP&E, net$191,000$199,000$212,000$310,000$399,000$445,000$816,000$961,000
Total assets$786.79M$264.56M$293.60M$332.64M$362.74M$194.60M$219.68M$193.63M
Current liabilities$29.05M$21.15M$15.97M$22.69M$25.79M$21.42M$17.93M$28.41M
Total liabilities$33.06M$25.40M$20.44M$27.39M$30.75M$26.72M$18.26M$28.87M
Shareholders' equity$753.74M$239.17M$273.16M$305.26M$332.00M$167.88M$201.42M$164.76M
Shares outstanding128.54M111.37M111.03M109.88M109.77M89.16M89.08M68.63M
Cash flow statement
Operating cash flow-$33.67M-$31.42M-$36.88M-$27.90M-$30.37M-$25.25M-$39.82M-$59.01M
Capital expenditure$25,000——$86,000$24,000$17,000$11,000$20,000
Free cash flow-$33.70M——-$27.99M-$30.39M-$25.27M-$39.84M-$59.03M
Investing cash flow-$325.67M-$149.80M$36.26M$29.47M$5.24M$22.99M-$43.66M$64.98M
Financing cash flow$550.16M$1.48M$3.22M-$208,000$191.61M-$31,000$65.66M$110,000
Depreciation & amortization$33,000$43,000$98,000$108,000$120,000$141,000$156,000$160,000
Stock-based compensation$10.37M$8.32M$6.12M$6.39M$7.08M$7.35M$6.83M$6.74M

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.